Entrectinib is a drug that inhibits TRKA, TRKB, TRKC, ROS1, and ALK, and following its approval for NTRK fusion gene-positive solid tumors, it has also been approved for ROS-1 fusion gene-mutated NSCLC. The gene discussed is ALK; the disease is non-small cell lung carcinoma.